NDAINJECTIONINJECTABLE
Approved
Dec 1975
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
3/8 — Basic
AMINOSYN 7% (PH6) (amino acids) by ICU Medical. Approved for chronic kidney disease stage 4, muscle atrophy, pressure ulcers and 10 more indications. First approved in 1975.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMINOSYN 7% (PH6) is an intravenous amino acid solution indicated for nutritional support in patients with chronic kidney disease, muscle atrophy, pressure ulcers, and cancer-related conditions. The product provides essential and non-essential amino acids in a formulation optimized for renal-impaired populations, supporting protein synthesis and metabolic recovery.
LOE Approaching
Product is in LOE phase with moderate competitive pressure (30/100); commercial teams should expect portfolio rationalization and cost-containment focus rather than growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on AMINOSYN 7% (PH6) at ICU Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.